Previous 10 | Next 10 |
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $60 (33% upside) price target at Jefferies. More news on: ACADIA Pharmaceuticals Inc., eHealth, Inc., Lumos Pharma, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
As the health crisis spirals into a financial one, the liquidation and panic selling have indiscriminately hit sectors across the board. The biotechs were no exception, with the S&P Biotech ETF ( XBI ) plummeting -20% on the year in tandem with the S&P 500 (SPY). Source: WingCapital...
Allakos (NASDAQ: ALLK ) initiated with Underperform rating and $34 (42% downside risk) price target at SMBC Nikko. More news on: Allakos Inc., Avadel Pharmaceuticals plc, Krystal Biotech, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
The only way of catching a train I have ever discovered is to miss the train before .”― G.K. Chesterton Markets continue to plunge on increasing worries around the outbreak of the coronavirus. The rise of Bernie Sanders in the polls as noted on CNBC are also not helpin...
Mirati Therapeutics (NASDAQ: MRTX ): Q4 GAAP EPS of -$1.83 misses by $0.40 . More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , Feb. 25, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full year-ended December 31, 2019 . "In 2019, we advanced MRTX849, our KRAS G12C inhibitor in...
SAN DIEGO , Feb. 19, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical stage targeted oncology company, today announced the grants of inducement non-qualified stock options to purchase an aggregate of 26,712 shares of common stock and an aggregate of 16,659 re...
SAN DIEGO , Feb. 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, today announced the presentation of initial data from an ongoing investigator sponsored Phase 1/2 clinical trial of sitravatinib in combination with nivolum...
Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...
Researchers at BMO Financial Group have initiated coverage of four companies in the biotech space, with one gaining an “outperform” rating. In an email to clients sent on Tuesday (January 28), the bank confirmed that its research analyst George Farmer will now cover BioMarin Ph...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...